Sara Sakowitz, Syed Shahyan Bakhtiyar, Saad Mallick, Yas Sanaiha, Ann Raldow, Peyman Benharash, Jane Yanagawa
{"title":"Association of Chemoradiation, Trimodality Therapy, or Salvage Resection with Survival in Stage II-III Esophageal Squamous Cell Carcinoma.","authors":"Sara Sakowitz, Syed Shahyan Bakhtiyar, Saad Mallick, Yas Sanaiha, Ann Raldow, Peyman Benharash, Jane Yanagawa","doi":"10.1016/j.jtcvs.2025.03.004","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Esophageal squamous cell carcinoma(ESCC) remains highly lethal and often under-treated. With conflicting evidence regarding the additional benefit of surgical resection to chemoradiation, many patients with locoregionally-advanced disease may receive chemoradiation and then undergo evaluation for progression before esophagectomy. We hypothesized that trimodality therapy or salvage resection would be linked with superior overall survival, relative to definitive chemoradiation.</p><p><strong>Methods: </strong>This retrospective analysis of the 2004-2021 National Cancer Database identified all clinically-staged II-III ESCC patients≥18years. Patients undergoing chemotherapy and ≥41.4 Grays of radiation across 28 fractions, followed by esophagectomy <90 days were considered the trimodality cohort, while those undergoing resection ≥90 days were classified as salvage. Patients receiving definitive chemoradiation were categorized as definitive CRT.</p><p><strong>Results: </strong>Of 3,786 patients, 912 (24%) underwent trimodality therapy, 173 (5%) chemoradiation followed by salvage resection, and 2,701 (71%) definitive CRT. Following risk-adjustment and relative to definitive CRT, trimodality was linked with greater survival at 1 (HR 0.45, CI 0.34-0.59) and 5 years (HR 0.57, CI 0.49-0.66), as was salvage (1 year: HR 0.38, CI 0.22-0.69; 5 year: HR 0.54, CI 0.40-0.73). Upon RMST analysis, trimodality demonstrated a 9.17 month (CI 6.40-11.94) incremental increase in overall survival time over 5 years, while salvage was linked with a 10.03 month (CI 4.04-16.03) increase in survival time, compared to definitive CRT.</p><p><strong>Conclusions: </strong>Surgical resection following chemoradiation confers survival benefit and should be considered a mainstay in the management of locoregionally-advanced ESCC. Yet, with comparable outcomes across trimodality and salvage approaches, organ preservation may be appropriate, for select patients.</p>","PeriodicalId":49975,"journal":{"name":"Journal of Thoracic and Cardiovascular Surgery","volume":" ","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic and Cardiovascular Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jtcvs.2025.03.004","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Esophageal squamous cell carcinoma(ESCC) remains highly lethal and often under-treated. With conflicting evidence regarding the additional benefit of surgical resection to chemoradiation, many patients with locoregionally-advanced disease may receive chemoradiation and then undergo evaluation for progression before esophagectomy. We hypothesized that trimodality therapy or salvage resection would be linked with superior overall survival, relative to definitive chemoradiation.
Methods: This retrospective analysis of the 2004-2021 National Cancer Database identified all clinically-staged II-III ESCC patients≥18years. Patients undergoing chemotherapy and ≥41.4 Grays of radiation across 28 fractions, followed by esophagectomy <90 days were considered the trimodality cohort, while those undergoing resection ≥90 days were classified as salvage. Patients receiving definitive chemoradiation were categorized as definitive CRT.
Results: Of 3,786 patients, 912 (24%) underwent trimodality therapy, 173 (5%) chemoradiation followed by salvage resection, and 2,701 (71%) definitive CRT. Following risk-adjustment and relative to definitive CRT, trimodality was linked with greater survival at 1 (HR 0.45, CI 0.34-0.59) and 5 years (HR 0.57, CI 0.49-0.66), as was salvage (1 year: HR 0.38, CI 0.22-0.69; 5 year: HR 0.54, CI 0.40-0.73). Upon RMST analysis, trimodality demonstrated a 9.17 month (CI 6.40-11.94) incremental increase in overall survival time over 5 years, while salvage was linked with a 10.03 month (CI 4.04-16.03) increase in survival time, compared to definitive CRT.
Conclusions: Surgical resection following chemoradiation confers survival benefit and should be considered a mainstay in the management of locoregionally-advanced ESCC. Yet, with comparable outcomes across trimodality and salvage approaches, organ preservation may be appropriate, for select patients.
目的:食管鳞状细胞癌(ESCC)仍然是高致死率且经常治疗不足的疾病。关于手术切除相对于放化疗的额外益处,有相互矛盾的证据,许多局部区域晚期疾病患者可能接受放化疗,然后在食管切除术前进行进展评估。我们假设,相对于明确的放化疗,三段式治疗或补救性切除与更高的总生存率有关。方法:对2004-2021年国家癌症数据库进行回顾性分析,确定所有临床分期II-III期ESCC患者≥18岁。结果:在3786例患者中,912例(24%)接受了三段式治疗,173例(5%)接受了放化疗后的补救性切除,2701例(71%)接受了最终的CRT。经过风险调整并相对于明确的CRT,三模态与更高的1年生存率(HR 0.45, CI 0.34-0.59)和5年生存率(HR 0.57, CI 0.49-0.66)相关,救助期(1年:HR 0.38, CI 0.22-0.69;5年:HR 0.54, CI 0.40-0.73)。根据RMST分析,与最终的CRT相比,三模态显示5年内总生存时间增加9.17个月(CI 6.40-11.94),而挽救与生存时间增加10.03个月(CI 4.04-16.03)相关。结论:放化疗后手术切除可获得生存益处,应被视为局部区域晚期ESCC治疗的主要方法。然而,在三段式和挽救性入路的比较结果中,器官保存可能适合于特定的患者。
期刊介绍:
The Journal of Thoracic and Cardiovascular Surgery presents original, peer-reviewed articles on diseases of the heart, great vessels, lungs and thorax with emphasis on surgical interventions. An official publication of The American Association for Thoracic Surgery and The Western Thoracic Surgical Association, the Journal focuses on techniques and developments in acquired cardiac surgery, congenital cardiac repair, thoracic procedures, heart and lung transplantation, mechanical circulatory support and other procedures.